Courtenay C. Brinckerhoff

Courtenay C. Brinckerhoff

Foley & Lardner LLP

Contact  |  View Bio  |  RSS

Latest Posts › Patent-Eligible Subject Matter

Share:

District Court Doubts Patent Eligibility of Myriad BRCA Claims

In a decision issued March 10, 2014, Judge Shelby of the U.S. District Court for the District of Utah denied Myriad’s motion for a preliminary injunction against Ambry Genetics Corp. While Ambry had challenged the validity of...more

3/19/2014 - Ambry AMP v Myriad BRCA Myriad Patent-Eligible Subject Matter Patents Preliminary Injunctions

Five Things You Should Know About the USPTO Patent Subject Matter Eligibility Guidelines

The new USPTO patent subject matter eligibility guidelines set forth a detailed analytical framework for evaluating whether claims satisfy the patent subject matter eligibility requirement of 35 USC § 101. If you are an...more

3/17/2014 - Biotechnology Life Sciences Patent Litigation Patent-Eligible Subject Matter Patents USPTO

Do Pharmaceutical Compositions Have Patent Subject Matter Eligibility Under the New USPTO Guidelines?

The USPTO’s new patent subject matter eligibility guidelines (the “Guidelines”) include examples that apply the multi-factored analysis mandated by the Guidelines to compositions that include one or more “natural products” as...more

3/11/2014 - Patent Litigation Patent-Eligible Subject Matter Patents Pharmaceutical USPTO

USPTO Issues New Guidelines on Subject Matter Eligibility Under 35 USC 101 in View of Myriad and Prometheus

The USPTO issued new guidelines for determining if claims are eligible for patenting in light of the Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S., 133 S. Ct. 2107, 2116, 106 USPQ2d 1972 (2013), and...more

3/6/2014 - Patent-Eligible Subject Matter USPTO

USPTO Issues New Patent Subject Matter Eligibility Guidelines

The USPTO has issued new patent subject matter eligibility guidelines to aid examiners in applying the principles of Myriad and Prometheus to any claim “reciting or involving laws of nature/natural principles, natural...more

3/5/2014 - AMP v Myriad Mayo v. Prometheus Myriad Patent-Eligible Subject Matter Patents USPTO

Federal Circuit Holds Computer-Implemented Method Claims Invalid Under Section 101

Although SmartGene, Inc. v. Advanced Biological Laboratories, SA is a non-precedential Federal Circuit decision, it could be interesting for that very reason, if it is a reflection of what the court sees as settled aspects of...more

2/5/2014 - Computer-Related Inventions Patent Applications Patent Litigation Patent-Eligible Subject Matter Patents

Federal Circuit Holds Full Sequence Not Required for Invention of DNA

In Sanofi-Aventis v. Pfizer, Inc., the Federal Circuit affirmed the USPTO’s determination that Pfizer had proven an earlier date of invention of the DNA sequence at issue, even though it did not have the full, correct...more

11/7/2013 - America Invents Act DNA Interference Proceeding Patent Reform Patent-Eligible Subject Matter Patents Pfizer Prior Art USPTO

Myriad Preliminary Injunction Hearing to Be Held September 11, 2013

The hearing on Myriad’s motion for a preliminary injunction against Ambry Genetics is scheduled for September 11, 2013, before Judge Robert A. Shelby at the U.S. District Court for the Central District of Utah....more

9/9/2013 - AMP v Myriad DNA Genetic Materials Human Genes Injunctions Myriad Patent Litigation Patent-Eligible Subject Matter Patents Preliminary Injunctions SCOTUS

Federal Circuit Remands Sequenom Down Syndrome Test Platform Patent for Consideration Under Myriad

In Aria Diagnostics, Inc. v. Sequenom, Inc., the Federal Circuit vacated and remanded the district court’s decision denying Sequenom’s motion for a preliminary injunction relating to a patent covering the non-invasive...more

8/13/2013 - AMP v Myriad DNA Genetic Testing Myriad Patent-Eligible Subject Matter Patents Preliminary Injunctions

Myriad’s Trade Secret Trump Card: The Myriad Database of Genetic Variants

One of the most interesting arguments that Myriad made in its Motion for Preliminary Injunctive Relief in its infringement action against Ambry Genetics Corporation relates to the database of genetic information that Myriad...more

7/18/2013 - AMP v Myriad Databases DNA Genetic Materials Injunctions Myriad Patent-Eligible Subject Matter Patents

Judge Rader Explains 35 USC 101 in Ultramercial v Hulu

In the June 21, 2013 Federal Circuit decision in Ultramercial, Inc. v. Hulu, LLC, the court again reversed the district court’s finding that the claims at issue fail to satisfy § 101....more

6/24/2013 - Motion to Dismiss Patent Infringement Patent-Eligible Subject Matter Patents

Supreme Court Holds Isolated Naturally Occurring DNA Cannot Be Patented, Sustains Patent-Eligibility of cDNA

On June 13, 2013, the U.S. Supreme Court issued its long-awaited decision in the “ACLU/Myriad” gene patenting case (formally, Association For Molecular Pathology. et al. v. Myriad Genetics, Inc., et al., Supreme Court No....more

6/14/2013 - AMP v Myriad Biotechnology DNA Human Genes Myriad Patent-Eligible Subject Matter Patents SCOTUS

Federal Circuit Issues Fractured Affirmance in CLS Bank v. Alice Corporation

In a fractured en banc decision, the Federal Circuit affirmed the district court’s holding that the claims at issue in CLS Bank v. Alice Corporation are invalid under 35 USC § 101. The multiple opinions reveal the judge’s...more

5/13/2013 - CLS Bank CLS Bank v Alice Corp Patent-Eligible Subject Matter Patents SCOTUS

Dispelling the Myriad Gene Patent Harmonization Myth

In the wake of the Supreme Court oral arguments in the Myriad “gene patent” case, most commentators are predicting that the Court will uphold the patent-eligibility of non-naturally occurring DNA sequences (such as cDNA), but...more

5/1/2013 - DNA EU Gene Patenting Human Genes Patent-Eligible Subject Matter

14 Results
|
View per page
Page: of 1